Fluoxymesterone
Android-f, Halotestin, Ora-testryl (fluoxymesterone) is a small molecule pharmaceutical. Fluoxymesterone was first approved as Ora-testryl on 1982-01-01. It is used to treat angioedema, breast neoplasms, and hypogonadism in the USA. The pharmaceutical is active against androgen receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| angioedema | EFO_0005532 | D000799 | T78.3 |
| breast neoplasms | EFO_0003869 | D001943 | C50 |
| hypogonadism | HP_0000815 | D007006 | E23.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
1629 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | 65 | 234 | 124 | 10 | 15 | 413 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 55 | 107 | 31 | 1 | 4 | 170 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 26 | 92 | 39 | 2 | 6 | 151 |
| Neoplasms | D009369 | C80 | 69 | 43 | 15 | 1 | 2 | 120 | |
| Esophageal neoplasms | D004938 | C15 | 24 | 74 | 27 | 2 | 5 | 115 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 9 | 34 | 60 | 2 | 6 | 108 |
| Adenocarcinoma | D000230 | 25 | 60 | 22 | 1 | 1 | 93 | ||
| Head and neck neoplasms | D006258 | 14 | 47 | 26 | 1 | 1 | 80 | ||
| Colonic neoplasms | D003110 | C18 | 15 | 24 | 17 | 1 | 4 | 54 | |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 8 | 25 | 16 | 1 | 8 | 53 |
Show 16 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rectal neoplasms | D012004 | 30 | 60 | 16 | — | 4 | 97 | ||
| Squamous cell carcinoma of head and neck | D000077195 | 12 | 27 | 14 | — | 1 | 47 | ||
| Nasopharyngeal neoplasms | D009303 | — | 20 | 17 | — | 3 | 37 | ||
| Pancreatic ductal carcinoma | D021441 | 12 | 14 | 4 | — | — | 24 | ||
| Esophageal squamous cell carcinoma | D000077277 | 2 | 10 | 13 | — | — | 24 | ||
| Squamous cell carcinoma | D002294 | 8 | 16 | 4 | — | — | 24 | ||
| Biliary tract neoplasms | D001661 | C24.9 | 4 | 18 | 2 | — | 1 | 22 | |
| Gallbladder neoplasms | D005706 | EFO_0004606 | C23 | 7 | 11 | 2 | — | 1 | 19 |
| Cholangiocarcinoma | D018281 | C22.1 | 5 | 11 | 3 | — | 1 | 19 | |
| Anus neoplasms | D001005 | EFO_0003835 | C21 | 4 | 10 | 6 | — | — | 18 |
Show 52 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | 9 | 10 | — | — | — | 16 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 9 | 9 | — | — | — | 15 |
| Peritoneal neoplasms | D010534 | 4 | 5 | — | — | 1 | 10 | ||
| Non-small-cell lung carcinoma | D002289 | 6 | 5 | — | — | — | 8 | ||
| Bile duct neoplasms | D001650 | 1 | 6 | — | — | — | 7 | ||
| Melanoma | D008545 | 6 | 3 | — | — | — | 6 | ||
| Endometrial neoplasms | D016889 | EFO_0004230 | 1 | 6 | — | — | — | 6 | |
| Acinar cell carcinoma | D018267 | 3 | 2 | — | — | — | 5 | ||
| Lymphoma | D008223 | C85.9 | 4 | 1 | — | — | — | 5 | |
| Urethral neoplasms | D014523 | EFO_0003846 | — | 4 | — | — | — | 4 |
Show 44 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | C61 | 3 | — | — | — | — | 3 | |
| Fallopian tube neoplasms | D005185 | 3 | — | — | — | — | 3 | ||
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 3 | — | — | — | — | 3 |
| Myelodysplastic syndromes | D009190 | D46 | 2 | — | — | — | — | 2 | |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | — | — | — | — | 1 | |
| Hematologic neoplasms | D019337 | 1 | — | — | — | — | 1 | ||
| Primary myelofibrosis | D055728 | D47.4 | 1 | — | — | — | — | 1 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 1 | — | — | — | — | 1 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 1 | — | — | — | — | 1 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | — | — | — | — | 1 |
Show 29 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | FLUOXYMESTERONE |
| INN | fluoxymesterone |
| Description | Fluoxymesterone is an anabolic androgenic steroid, a 17beta-hydroxy steroid, an 11beta-hydroxy steroid, a fluorinated steroid and a 3-oxo-Delta(4) steroid. It has a role as an antineoplastic agent and an anabolic agent. |
| Classification | Small molecule |
| Drug class | steroids (androgens, anabolics); antiandrogens |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C |
Identifiers
| PDB | — |
| CAS-ID | 76-43-7 |
| RxCUI | 4494 |
| ChEMBL ID | CHEMBL1445 |
| ChEBI ID | 5120 |
| PubChem CID | 6446 |
| DrugBank | DB01185 |
| UNII ID | 9JU12S4YFY (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 478 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
56,223 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more